{"Abstract": [0], "Glioblastoma": [1], "is": [2, 18, 28, 79, 138, 151], "the": [3, 11, 45, 100, 111, 115, 145, 182, 186, 196, 213], "most": [4], "common": [5], "malignant": [6], "primary": [7], "brain": [8], "tumor.": [9], "Overall,": [10], "prognosis": [12], "for": [13, 155], "patients": [14, 216], "with": [15, 20, 37, 55, 73, 90, 205, 217], "this": [16], "disease": [17, 112], "poor,": [19], "a": [21, 29, 139, 152], "median": [22], "survival": [23], "of": [24, 82, 124, 141, 144, 148, 198, 215], "&lt;2": [25], "years.": [26], "There": [27, 150], "slight": [30], "predominance": [31], "in": [32, 44, 114, 195], "males,": [33], "and": [34, 57, 87, 104, 159, 167, 185, 189], "incidence": [35], "increases": [36], "age.": [38], "The": [39, 120], "standard": [40, 81], "approach": [41, 117], "to": [42, 118, 173, 210], "therapy": [43, 89], "newly": [46], "diagnosed": [47], "setting": [48], "includes": [49], "surgery": [50], "followed": [51], "by": [52], "concurrent": [53], "radiotherapy": [54], "temozolomide": [56], "further": [58], "adjuvant": [59, 74], "temozolomide.": [60, 75], "Tumor\u2010treating": [61], "fields,": [62, 67], "delivering": [63], "low\u2010intensity": [64], "alternating": [65], "electric": [66], "can": [68], "also": [69], "be": [70], "given": [71], "concurrently": [72], "At": [76], "recurrence,": [77], "there": [78, 160], "no": [80], "care;": [83], "however,": [84, 177], "surgery,": [85], "radiotherapy,": [86], "systemic": [88], "chemotherapy": [91], "or": [92], "bevacizumab": [93], "are": [94, 208], "all": [95], "potential": [96], "options,": [97, 158], "depending": [98], "on": [99, 127], "patient's": [101], "circumstances.": [102], "Supportive": [103], "palliative": [105], "care": [106], "remain": [107], "important": [108], "considerations": [109], "throughout": [110], "course": [113], "multimodality": [116], "management.": [119], "recently": [121], "revised": [122], "classification": [123], "glioblastoma": [125], "based": [126], "molecular": [128], "profiling,": [129], "notably": [130], "isocitrate": [131], "dehydrogenase": [132], "(": [133], "IDH": [134], ")": [135], "mutation": [136], "status,": [137], "result": [140], "enhanced": [142], "understanding": [143], "underlying": [146], "pathogenesis": [147], "disease.": [149], "clear": [153], "need": [154], "better": [156], "therapeutic": [157], "have": [161], "been": [162], "substantial": [163], "efforts": [164], "exploring": [165], "immunotherapy": [166], "precision": [168], "oncology": [169], "approaches.": [170], "In": [171], "contrast": [172], "other": [174], "solid": [175], "tumors,": [176], "biological": [178], "factors,": [179], "such": [180], "as": [181], "blood\u2010brain": [183], "barrier": [184], "unique": [187], "tumor": [188], "immune": [190], "microenvironment,": [191], "represent": [192], "significant": [193], "challenges": [194], "development": [197], "novel": [199], "therapies.": [200], "Innovative": [201], "clinical": [202], "trial": [203], "designs": [204], "biomarker\u2010enrichment": [206], "strategies": [207], "needed": [209], "ultimately": [211], "improve": [212], "outcome": [214], "glioblastoma.": [218]}